Ben Sousa Sells 2,250 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) insider Ben Sousa sold 2,250 shares of ICU Medical stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the sale, the insider owned 3,076 shares of the company’s stock, valued at $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $183.11 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. The firm has a market cap of $4.58 billion, a price-to-earnings ratio of 155.18, a price-to-earnings-growth ratio of 2.51 and a beta of 0.74. The business has a 50-day simple moving average of $155.63 and a two-hundred day simple moving average of $141.67. ICU Medical, Inc. has a fifty-two week low of $111.42 and a fifty-two week high of $192.85.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter last year, the firm posted $2.10 EPS. The business’s quarterly revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current year.

Key Headlines Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 results beat expectations. ICU Medical reported adjusted earnings of $2.37 per share, well above the $1.91 analyst consensus, while revenue of $547.88 million exceeded estimates of $533.44 million. Revenue increased modestly year over year, and the company maintained fiscal 2026 EPS guidance of $8.60 to $9.00. ICU Medical Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analyst sentiment remains supportive. Following the earnings release, Needham raised its price target to $187, Piper Sandler to $195, and BTIG Research to $200, while maintaining positive ratings. Raymond James also reiterated its strong-buy rating with a $200 target. The consensus rating is “Moderate Buy,” with an average target of $192.80.
• Positive Sentiment: Investor attention remains focused on the earnings call. Analysts’ questions centered on the company’s quarterly performance and outlook, suggesting that the earnings beat and management’s commentary remain the key drivers of current trading interest. The 5 Most Interesting Analyst Questions From ICU Medical’s Q2 Earnings Call
• Neutral Sentiment: Valuation is demanding. ICU Medical trades near its 52-week high at a very elevated forward valuation, making the stock more sensitive to any slowdown in growth or signs that the recent earnings momentum cannot be sustained.
• Negative Sentiment: Several insiders sold shares. Vice President Daniel Woolson sold 5,417 shares for approximately $982,000, COO Christian Voigtlander sold 8,929 shares for about $1.63 million, CIO Ben Sousa sold 2,250 shares for $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The transactions reduced their holdings by meaningful percentages and may raise concerns about insider conviction, although such sales can also reflect personal liquidity or diversification. ICU Medical Insider Sales

Wall Street Analysts Forecast Growth

ICUI has been the subject of a number of research analyst reports. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Raymond James Financial reissued a “strong-buy” rating and set a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. KeyCorp lifted their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Needham & Company LLC upped their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $192.80.

Institutional Trading of ICU Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in ICU Medical in the second quarter worth approximately $550,250,000. Millennium Management LLC grew its position in shares of ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after acquiring an additional 690,694 shares during the period. Norges Bank bought a new stake in shares of ICU Medical during the 4th quarter valued at $58,083,000. Reinhart Partners LLC. bought a new stake in shares of ICU Medical during the 2nd quarter valued at $46,148,000. Finally, Thrivent Financial for Lutherans increased its stake in shares of ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after purchasing an additional 285,648 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.